ACADIA Pharmaceuticals Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report; fourth-quarter figures are included where useful. ACADIA is a CNS-focused biopharmaceutical company whose lead drug, NUPLAZID (pimavanserin), was FDA-approved for Parkinson’s disease psychosis (PD Psychosis) in April 2016 and launched in the U.S. in May 2016.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $17.3 million, including $17.3 million in net product sales | $0.1 million |
| Cost of product sales | $3.1 million | — |
| Gross profit / margin on product sales | $14.3 million / approximately 82% | — |
| Research and development | $99.3 million | $73.9 million |
| Selling, general and administrative | $186.5 million | $88.3 million |
| Operating loss | $272.8 million | $164.6 million |
| Net loss | $271.4 million; $2.34 per share | $164.4 million; $1.63 per share |
| Net cash used in operations | $210.4 million | $121.8 million |
| Cash, cash equivalents and investments at year-end | $529.0 million | $215.1 million |
| Working capital at year-end | $505.3 million | $197.1 million |
Fourth quarter: Revenue was $12.0 million, gross profit $10.3 million, net loss $78.7 million, and basic and diluted loss per share $0.65.
At year-end, total assets were $561.2 million, total liabilities $42.7 million, and stockholders’ equity $518.4 million. The balance sheet lists no borrowings; the filing reports no material off-balance-sheet arrangements. Operating cash outflow increased as commercialization and development spending expanded. Cash flow from financing included approximately $497.5 million net proceeds from two 2016 stock offerings and $14.3 million from a settlement agreement. Shares outstanding rose to 121.4 million at year-end from 101.9 million.
Material changes versus prior year
- 2016 was ACADIA’s first year of product revenue following NUPLAZID approval and launch; reported net product sales were $17.3 million. Revenue recognition used a sell-through method, with $2.6 million of deferred revenue at year-end.
- Net loss widened by $107.0 million. SG&A more than doubled, mainly reflecting launch preparation, commercial services, and hiring a specialty sales force; R&D rose 34% as clinical development expanded.
- Cash and investments increased by $313.9 million, primarily from equity offerings, while cash used in operating activities increased by $88.6 million.
- Management said adoption of the new revenue standard, expected in 2018, would materially affect the financial statements and result in earlier revenue recognition through estimated sales allowances.
Business outlook, commentary and risks
- Management expected operating losses for at least the next few years as it funded the U.S. launch, post-marketing commitments and additional pimavanserin trials. It believed available cash and investments would fund planned operations through at least the next 12 months; no revenue, earnings or cash-flow guidance was provided.
- Pipeline priorities included a planned Phase III AD Psychosis study in the second half of 2017, plus Phase II Alzheimer’s agitation, schizophrenia negative-symptom and major-depressive-disorder studies, and a Phase III adjunctive schizophrenia study. The Phase II AD Psychosis trial met its six-week primary endpoint (p=0.0451), but the week-12 secondary endpoint did not statistically separate from placebo.
- Key risks include dependence on successful NUPLAZID commercialization, uncertain diagnosis and uptake, pricing and reimbursement pressure, and the product’s boxed warning concerning increased mortality in elderly patients with dementia-related psychosis. FDA post-marketing studies and continued safety monitoring could affect labeling or approval.
- Supply is concentrated in one commercial API supplier and one drug-product manufacturer; four U.S. customers represented about 93% of 2016 revenue. Disruptions, quality issues or customer concentration could impair sales.
- A securities class action concerning earlier statements about the planned NUPLAZID filing was agreed in principle to settle after the court denied a motion to dismiss. ACADIA accrued $483,000 for anticipated settlement costs; final settlement terms are not stated here.
- ACADIA reported an accumulated deficit of $934.0 million and full valuation allowances against deferred tax assets. Future financing may be needed and could dilute shareholders.
Most important facts for investors to verify
- Subsequent quarterly NUPLAZID sales, prescription trends, patient continuation after free-trial offers, and net pricing after rebates and discounts.
- Coverage, reimbursement and gross-to-net adjustments, including Medicare Part D exposure, and whether sales growth can support the commercial cost base.
- Progress and results of post-marketing safety commitments and the AD Psychosis, Alzheimer’s agitation, schizophrenia and depression trials.
- Cash burn, investment balances and management’s stated runway, particularly as clinical and commercial spending continues.
- Supply-chain resilience, customer concentration, the final status and cost of the securities settlement, and potential dilution from future equity financing.